{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+DISKUS", "query": { "intervention": "placebo DISKUS" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 43, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+DISKUS&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T19:41:41.703Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02433834", "title": "Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Glycopyrronium MDI", "type": "DRUG" }, { "name": "Serevent Diskus 50 μg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pearl Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 248, "start_date": "2015-05-27", "completion_date": "2016-03-26", "has_results": true, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-09-03T19:41:41.703Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02433834" }, { "nct_id": "NCT02730351", "title": "Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone furoate/ Vilanterol 100 mcg/25 mcg", "type": "DRUG" }, { "name": "Fluticasone propionate 250 mcg", "type": "DRUG" }, { "name": "Placebo via ELLIPTA inhaler", "type": "DRUG" }, { "name": "Placebo via DISKUS / ACCUHALER", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": 75, "start_date": "2016-05-25", "completion_date": "2017-02-03", "has_results": true, "last_update_posted_date": "2019-07-16", "last_synced_at": "2026-09-03T19:41:41.703Z", "location_count": 13, "location_summary": "Huntington Beach, California • Los Angeles, California • San Diego, California + 9 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02730351" }, { "nct_id": "NCT02245672", "title": "MGR001 / Advair Diskus Local Equivalence Study in Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)", "type": "DRUG" }, { "name": "Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharma UK Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1128, "start_date": "2014-10", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2022-02-24", "last_synced_at": "2026-09-03T19:41:41.703Z", "location_count": 101, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 84 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02245672" }, { "nct_id": "NCT00605891", "title": "Dose Finding Study of CHF 4226 for Treating Patients With COPD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "carmoterol (CHF 4226)", "type": "DRUG" }, { "name": "salmeterol", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chiesi Farmaceutici S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 278, "start_date": "2006-10", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2017-04-11", "last_synced_at": "2026-09-03T19:41:41.703Z", "location_count": 24, "location_summary": "Jonesboro, Arkansas • Fresno, California • San Diego, California + 19 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00605891" }, { "nct_id": "NCT01147744", "title": "Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone Propionate 100mcg via ACCUHALER/DISKUS", "type": "DRUG" }, { "name": "GSK2190915 100mg", "type": "DRUG" }, { "name": "GSK2190915 10mg", "type": "DRUG" }, { "name": "GSK2190915 300mg", "type": "DRUG" }, { "name": "GSK2190915 30mg", "type": "DRUG" }, { "name": "Montelukast 10mg", "type": "DRUG" }, { "name": "Placebo GSK2190915 one tablet", "type": "DRUG" }, { "name": "Placebo montelukast", "type": "DRUG" }, { "name": "Placebo fluticasone propionate via ACCUHALER/DISKUS", "type": "DRUG" }, { "name": "Placebo GSK2190915 two tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "FEMALE", "summary": "12 Years and older · Female only" }, "enrollment_count": 700, "start_date": "2010-06-28", "completion_date": "2011-10-06", "has_results": true, "last_update_posted_date": "2017-10-02", "last_synced_at": "2026-09-03T19:41:41.703Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Huntington Beach, California • Newport Beach, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147744" }, { "nct_id": "NCT03756883", "title": "Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone Propionate and Salmeterol Inhalation Powder", "type": "DRUG" }, { "name": "Placebo Inhalation Powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 999, "start_date": "2018-12-03", "completion_date": "2019-11-10", "has_results": true, "last_update_posted_date": "2021-09-24", "last_synced_at": "2026-09-03T19:41:41.703Z", "location_count": 1, "location_summary": "Miami Lakes, Florida", "locations": [ { "city": "Miami Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03756883" }, { "nct_id": "NCT03394989", "title": "BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bronchial Asthma" ], "interventions": [ { "name": "Fluticasone propionate/salmeterol 100/50 µg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Cipla Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1366, "start_date": "2018-10-17", "completion_date": "2020-03-31", "has_results": false, "last_update_posted_date": "2020-08-13", "last_synced_at": "2026-09-03T19:41:41.703Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03394989" }, { "nct_id": "NCT03535870", "title": "Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone propionate/salmeterol", "type": "DRUG" }, { "name": "Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West-Ward Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 1556, "start_date": "2018-04-26", "completion_date": "2019-09-10", "has_results": false, "last_update_posted_date": "2019-11-29", "last_synced_at": "2026-09-03T19:41:41.703Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT03535870" }, { "nct_id": "NCT01089127", "title": "Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Indacaterol", "type": "DRUG" }, { "name": "Salmeterol 50 μg", "type": "DRUG" }, { "name": "Placebo to indacaterol", "type": "DRUG" }, { "name": "Placebo to salmeterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 552, "start_date": "2010-03", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2011-08-19", "last_synced_at": "2026-09-03T19:41:41.703Z", "location_count": 69, "location_summary": "Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more", "locations": [ { "city": "Florence", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01089127" }, { "nct_id": "NCT01079130", "title": "Efficacy and Safety of Different Doses of Indacaterol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Indacaterol", "type": "DRUG" }, { "name": "Salmeterol", "type": "DRUG" }, { "name": "Placebo to Indacaterol", "type": "DRUG" }, { "name": "Placebo to Salmeterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 511, "start_date": "2010-02", "completion_date": null, "has_results": true, "last_update_posted_date": "2011-08-19", "last_synced_at": "2026-09-03T19:41:41.703Z", "location_count": 71, "location_summary": "Glendale, Arizona • Scottsdale, Arizona • Encinitas, California + 64 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01079130" } ] }